Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide in Pediatric Cardiopulmonary Bypass
NCT05101746Phase 3Enrolling by invitation
- Sponsor
- Vanderbilt University Medical Center
- Start
- Apr 2022
- Primary completion
- Sep 2026
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in congenital heart disease (CHD) comparing Nitric oxide group with Standard of care (2 arms). Primary endpoints: Glial Fibrillary Acid Protein at 3 hours and Neutrophil Gelatinase-Associated Lipocalin at 2 hours. Started Apr 2022; status: enrolling by invitation.
02
Drugs
nitric oxide
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT05101746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101746.